Fresenius SE & Co. KGaA (FRA:FRE) Given a €30.00 Price Target by Credit Suisse Group Analysts

Fresenius SE & Co. KGaA (FRA:FRE – Get Rating) received a €30.00 ($30.93) price objective from equities researchers at Credit Suisse Group in a report issued on Friday, Borsen Zeitung reports. Credit Suisse Group’s target price would indicate a potential upside of 23.81% from the company’s previous close.

A number of other analysts have also commented on the company. set a €36.00 ($37.11) price objective on Fresenius SE & Co. KGaA in a research note on Friday, July 29th. UBS Group set a €30.00 ($30.93) price objective on Fresenius SE & Co. KGaA in a research note on Thursday, June 23rd. Berenberg Bank set a €60.25 ($62.11) price target on Fresenius SE & Co. KGaA in a research note on Friday, April 29th. Warburg Research set a €42.00 ($43.30) price target on Fresenius SE & Co. KGaA in a research note on Friday. Finally, JPMorgan Chase & Co. set a €33.30 ($34.33) price target on Fresenius SE & Co. KGaA in a research note on Monday, July 18th.

Fresenius SE & Co. KGaA Stock Up 0.6 %

Shares of FRE traded up €0.15 ($0.15) during trading hours on Friday, reaching €24.23 ($24.98). 1,383,900 shares of the company traded hands. Fresenius SE & Co. KGaA has a fifty-two week low of €60.16 ($62.02) and a fifty-two week high of €80.00 ($82.47). The stock has a fifty day simple moving average of €28.51 and a 200 day simple moving average of €31.96.

Fresenius SE & Co. KGaA Company Profile

(Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.